MedTrace Logo

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 731

Last updated 2026-03-12

No results posted yet for this study

Summary

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Conditions

Interventions

DRUG

JNJ-77242113

JNJ-77242113 will be administered orally.

DRUG

JNJ-77242113 Matching Placebo

JNJ-77242113 matching placebo will be administered orally.

DRUG

Deucravacitinib

Deucravacitinib will be administered orally.

DRUG

Deucravacitinib Matching Placebo

Deucravacitinib matching placebo will be administered orally.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinicaltrial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-09
Primary Completion
2024-11-15
Completion
2027-09-20
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • Germany
  • Hungary
  • Poland
  • Romania
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06220604 on ClinicalTrials.gov